{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:33:20Z","timestamp":1793190800793,"version":"4.5.0"},"reference-count":102,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","translationalres.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Research"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.trsl.2026.10.004","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:57:27Z","timestamp":1792079847000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ocular Immune Toxicity in Cancer Immunotherapy, From Immune Privilege Breakdown to Treatment Rechallenge: A Review"],"prefix":"10.1016","author":[{"given":"Kai-Yang","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoi-Chun","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6981-3411","authenticated-orcid":false,"given":"Chi-Ming","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.trsl.2026.10.004_bib0001","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/09273948.2020.1781902","article-title":"Immune Checkpoint Inhibitor-associated Uveitis: Review of Treatments and Outcomes","volume":"29","author":"Dow","year":"2021","journal-title":"Ocul Immunol Inflamm"},{"issue":"1","key":"10.1016\/j.trsl.2026.10.004_bib0002","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 Pathways","volume":"39","author":"Buchbinder","year":"2016","journal-title":"American Journal of Clinical Oncology"},{"key":"10.1016\/j.trsl.2026.10.004_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinsp.2023.100177","article-title":"Programmed cell death-1 and its ligands: Current knowledge and possibilities in immunotherapy","volume":"78","author":"Gutic","year":"2023","journal-title":"Clinics (Sao Paulo)"},{"issue":"3","key":"10.1016\/j.trsl.2026.10.004_bib0004","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s10555-021-09976-0","article-title":"Inhibitors of immune checkpoints-PD-1, PD-L1, CTLA-4-new opportunities for cancer patients and a new challenge for internists and general practitioners","volume":"40","author":"Wojtukiewicz","year":"2021","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.trsl.2026.10.004_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104808","article-title":"T Cell-Mediated Mechanisms of Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors","volume":"213","author":"Li","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"issue":"17","key":"10.1016\/j.trsl.2026.10.004_bib0006","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.3390\/jcm11174993","article-title":"Ocular Inflammation Induced by Immune Checkpoint Inhibitors","volume":"11","author":"Chaudot","year":"2022","journal-title":"J Clin Med"},{"issue":"6","key":"10.1016\/j.trsl.2026.10.004_bib0007","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.3390\/biomedicines12061319","article-title":"Neurological Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors","volume":"12","author":"Stavropoulou De Lorenzo","year":"2024","journal-title":"Biomedicines"},{"issue":"6","key":"10.1016\/j.trsl.2026.10.004_bib0008","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.it.2019.04.002","article-title":"Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities","volume":"40","author":"Pauken","year":"2019","journal-title":"Trends in Immunology"},{"issue":"11","key":"10.1016\/j.trsl.2026.10.004_bib0009","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.3390\/ijms21113962","article-title":"Immune Checkpoints Contribute Corneal Immune Privilege: Implications for Dry Eye Associated with Checkpoint Inhibitors","volume":"21","author":"Hori","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.trsl.2026.10.004_bib0010","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/ICU.0000000000000931","article-title":"Perturbations of the ocular surface microbiome and their effect on host immune function","volume":"34","author":"Chang","year":"2023","journal-title":"Curr Opin Ophthalmol"},{"issue":"6","key":"10.1016\/j.trsl.2026.10.004_bib0011","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1080\/09273948.2019.1583347","article-title":"Ocular Adverse Events following Use of Immune Checkpoint Inhibitors for Metastatic Malignancies","volume":"28","author":"Noble","year":"2020","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.trsl.2026.10.004_bib0012","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jtos.2021.02.004","article-title":"Ocular surface disease associated with immune checkpoint inhibitor therapy","volume":"20","author":"Park","year":"2021","journal-title":"The Ocular Surface"},{"issue":"1","key":"10.1016\/j.trsl.2026.10.004_bib0013","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12348-022-00321-2","article-title":"Ocular adverse events associated with immune checkpoint inhibitors, a scoping review","volume":"13","author":"Martens","year":"2023","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"10.1016\/j.trsl.2026.10.004_bib0014","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ajo.2024.12.028","article-title":"Pathogenic Mechanisms of Immune Checkpoint Inhibitor (ICI)-Associated Retinal and Choroidal Adverse Reactions","volume":"272","author":"Haliyur","year":"2025","journal-title":"American Journal of Ophthalmology"},{"issue":"1","key":"10.1016\/j.trsl.2026.10.004_bib0015","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ygyno.2022.05.003","article-title":"Immunotherapy toxicities: An SGO clinical practice statement","volume":"166","author":"O'Cearbhaill","year":"2022","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.trsl.2026.10.004_bib0016","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primers"},{"issue":"12","key":"10.1016\/j.trsl.2026.10.004_bib0017","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1007\/s00262-020-02635-3","article-title":"Factors associated with ocular adverse event after immune checkpoint inhibitor treatment","volume":"69","author":"Kim","year":"2020","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"10.1016\/j.trsl.2026.10.004_bib0018","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1130238","article-title":"Ophthalmic immune-related adverse events associated with immune checkpoint inhibitors","volume":"14","author":"Gan","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.trsl.2026.10.004_bib0019","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12348-022-00323-0","article-title":"Clinical relationship between dry eye disease and uveitis: a scoping review","volume":"13","author":"Rojas-Carabali","year":"2023","journal-title":"J Ophthalmic Inflamm Infect"},{"issue":"1","key":"10.1016\/j.trsl.2026.10.004_bib0020","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4103\/sjopt.sjopt_296_23","article-title":"Immune checkpoint monoclonal antibody-related adverse effects in neuro-ophthalmology","volume":"38","author":"Ameri","year":"2024","journal-title":"Saudi Journal of Ophthalmology"},{"issue":"4","key":"10.1016\/j.trsl.2026.10.004_bib0021","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-011049","article-title":"Consensus disease definitions for ophthalmic immune-related adverse events of immune checkpoint inhibitors","volume":"13","author":"Chang","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"6","key":"10.1016\/j.trsl.2026.10.004_bib0022","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.ophtha.2020.11.001","article-title":"Ophthalmic Immune-Related Adverse Events after Anti-CTLA-4 or PD-1 Therapy Recorded in the American Academy of Ophthalmology Intelligent Research in Sight Registry","volume":"128","author":"Sun","year":"2021","journal-title":"Ophthalmology"},{"issue":"15","key":"10.1016\/j.trsl.2026.10.004_bib0023","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241512090","article-title":"Ocular Vascular Diseases: From Retinal Immune Privilege to Inflammation","volume":"24","author":"Wang","year":"2023","journal-title":"International Journal of Molecular Sciences"},{"issue":"2","key":"10.1016\/j.trsl.2026.10.004_bib0024","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.immuni.2024.01.010","article-title":"LAG-3, TIM-3, and TIGIT: Distinct functions in immune regulation","volume":"57","author":"Joller","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.trsl.2026.10.004_bib0025","first-page":"127","article-title":"Tim-3, Lag-3, and TIGIT","volume":"410","author":"Joller","year":"2017","journal-title":"Curr Top Microbiol Immunol"},{"issue":"1","key":"10.1016\/j.trsl.2026.10.004_bib0026","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-024-02023-w","article-title":"Regulatory mechanisms of PD-1\/PD-L1 in cancers","volume":"23","author":"Lin","year":"2024","journal-title":"Molecular cancer"},{"issue":"1","key":"10.1016\/j.trsl.2026.10.004_bib0027","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1167\/iovs.08-2397","article-title":"PD-L1 expression on human ocular cells and its possible role in regulating immune-mediated ocular inflammation","volume":"50","author":"Yang","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"11","key":"10.1016\/j.trsl.2026.10.004_bib0028","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.3390\/biomedicines12112547","article-title":"Emerging Ocular Side Effects of Immune Checkpoint Inhibitors: A Comprehensive Review","volume":"12","author":"Wu","year":"2024","journal-title":"Biomedicines"},{"issue":"5","key":"10.1016\/j.trsl.2026.10.004_bib0029","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0063620","article-title":"Galectin-9-Mediated Protection from Allo-Specific T Cells as a Mechanism of Immune Privilege of Corneal Allografts","volume":"8","author":"Shimmura-Tomita","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.trsl.2026.10.004_bib0030","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/imr.12520","article-title":"Tim-3 and its role in regulating anti-tumor immunity","volume":"276","author":"Das","year":"2017","journal-title":"Immunological Reviews"},{"issue":"21","key":"10.1016\/j.trsl.2026.10.004_bib0031","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.18632\/oncotarget.26771","article-title":"The immune checkpoint molecules PD-1, PD-L1, TIM-3 and LAG-3 in diffuse large B-cell lymphoma","volume":"10","author":"Chen","year":"2019","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.trsl.2026.10.004_bib0032","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.3390\/cancers15092615","article-title":"Immune Checkpoint Profiling in Humanized Breast Cancer Mice Revealed Cell-Specific LAG-3\/PD-1\/TIM-3 Co-Expression and Elevated PD-1\/TIM-3 Secretion","volume":"15","author":"Bruss","year":"2023","journal-title":"Cancers"},{"issue":"29","key":"10.1016\/j.trsl.2026.10.004_bib0033","doi-asserted-by":"crossref","first-page":"27359","DOI":"10.18632\/oncotarget.4751","article-title":"LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model","volume":"6","author":"Huang","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.trsl.2026.10.004_bib0034","doi-asserted-by":"crossref","first-page":"ltaf015","DOI":"10.1093\/immadv\/ltaf015","article-title":"Lag3 and PD-1 pathways preferentially regulate NFAT-dependent TCR signalling programmes during early CD4+ T cell activation","volume":"5","author":"Sheriff","year":"2025","journal-title":"Immunother Adv"},{"issue":"5","key":"10.1016\/j.trsl.2026.10.004_bib0035","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70345","article-title":"Unravelling T cell exhaustion through co-inhibitory receptors and its transformative role in cancer immunotherapy","volume":"15","author":"Xiang","year":"2025","journal-title":"Clin Transl Med"},{"issue":"3","key":"10.1016\/j.trsl.2026.10.004_bib0036","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.tcb.2020.12.001","article-title":"Signaling Dynamics Regulating Crosstalks between T-Cell Activation and Immune Checkpoints","volume":"31","author":"Kreileder","year":"2021","journal-title":"Trends Cell Biol"},{"issue":"12","key":"10.1016\/j.trsl.2026.10.004_bib0037","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2310866121","article-title":"Structural insights reveal interplay between LAG-3 homodimerization, ligand binding, and function","volume":"121","author":"Silberstein","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.trsl.2026.10.004_bib0038","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.956090","article-title":"The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application","volume":"13","author":"Huo","year":"2022","journal-title":"Frontiers in Immunology"},{"issue":"11","key":"10.1016\/j.trsl.2026.10.004_bib0039","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1158\/2326-6066.CIR-19-0146","article-title":"PD-1 and LAG-3 Dominate Checkpoint Receptor\u2013Mediated T-cell Inhibition in Renal Cell Carcinoma","volume":"7","author":"Zelba","year":"2019","journal-title":"Cancer Immunology Research"},{"issue":"11","key":"10.1016\/j.trsl.2026.10.004_bib0040","first-page":"970","article-title":"PD-1 and LAG-3 dual blockade: emerging mechanisms and potential therapeutic prospects in cancer","volume":"21","author":"Qiu","year":"2024","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.trsl.2026.10.004_bib0041","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1000023","article-title":"Case report: Immune-mediated meibomian gland dysfunction following pembrolizumab therapy for advanced urothelial carcinoma","volume":"12","author":"Nguyen","year":"2022","journal-title":"Frontiers in Oncology"},{"issue":"5","key":"10.1016\/j.trsl.2026.10.004_bib0042","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.21037\/tcr-23-1952","article-title":"Corneal ulcer development due to sintilimab-anlotinib combination therapy-induced dry eye: a case report","volume":"13","author":"Xiang","year":"2024","journal-title":"Translational Cancer Research"},{"issue":"7-8","key":"10.1016\/j.trsl.2026.10.004_bib0043","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1080\/09273948.2020.1766082","article-title":"Ocular Complications of Checkpoint Inhibitors and Immunotherapeutic Agents: A Case Series","volume":"29","author":"Parikh","year":"2021","journal-title":"Ocular Immunology and Inflammation"},{"issue":"7","key":"10.1016\/j.trsl.2026.10.004_bib0044","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.3390\/diagnostics11071240","article-title":"Challenging Mimickers in the Diagnosis of Sarcoidosis: A Case Study","volume":"11","author":"El Jammal","year":"2021","journal-title":"Diagnostics"},{"key":"10.1016\/j.trsl.2026.10.004_bib0045","article-title":"Recent Developments in HLA B27 Anterior Uveitis","volume":"11","author":"Wakefield","year":"2020","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.trsl.2026.10.004_bib0046","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/14737140.2017.1296765","article-title":"Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review","volume":"17","author":"Abdel-Rahman","year":"2017","journal-title":"Expert Review of Anticancer Therapy"},{"issue":"3","key":"10.1016\/j.trsl.2026.10.004_bib0047","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop","volume":"140","author":"Jabs","year":"2005","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.trsl.2026.10.004_bib0048","doi-asserted-by":"crossref","first-page":"100","DOI":"10.7861\/clinmed.2022-0046","article-title":"Inflammatory eye disease: An overview of clinical presentation and management","volume":"22","author":"Miller","year":"2022","journal-title":"Clinical Medicine"},{"issue":"6","key":"10.1016\/j.trsl.2026.10.004_bib0049","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1080\/09273948.2019.1610460","article-title":"Retinal Vasculitis Associated with Ipilimumab","volume":"28","author":"Tsui","year":"2019","journal-title":"Ocular Immunology and Inflammation"},{"key":"10.1016\/j.trsl.2026.10.004_bib0050","doi-asserted-by":"crossref","DOI":"10.3389\/fopht.2022.1044904","article-title":"Neuro-ophthalmic complications of immune checkpoint inhibitor therapy: Current status and future directions","volume":"2","author":"Winges","year":"2022","journal-title":"Frontiers in Ophthalmology"},{"key":"10.1016\/j.trsl.2026.10.004_bib0051","doi-asserted-by":"crossref","DOI":"10.7759\/cureus.66611","article-title":"Clinical Patterns and Factors Contributing to Ophthalmic and Otologic Events Associated With Immune Checkpoint Inhibitors: A Narrative Review","author":"Sunyur","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.trsl.2026.10.004_bib0052","article-title":"Ocular Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Lung Cancer","volume":"12","author":"Zhou","year":"2021","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.trsl.2026.10.004_bib0053","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.ajo.2024.08.044","article-title":"Ophthalmic Immune-Related Adverse Events and Association with Survival: Results From a Real-World Database","volume":"268","author":"Quiruz","year":"2024","journal-title":"American Journal of Ophthalmology"},{"issue":"3","key":"10.1016\/j.trsl.2026.10.004_bib0054","doi-asserted-by":"crossref","first-page":"NP29","DOI":"10.1177\/11206721231222659","article-title":"Bilateral retrobulbar optic neuritis combined with optic perineuritis associated with atezolizumab treatment for small cell lung carcinoma","volume":"34","author":"Zhang","year":"2024","journal-title":"Eur J Ophthalmol"},{"issue":"7","key":"10.1016\/j.trsl.2026.10.004_bib0055","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1182\/bloodadvances.2020003080","article-title":"Functional characterization of PD1+TIM3+ tumor-infiltrating T cells in DLBCL and effects of PD1 or TIM3 blockade","volume":"5","author":"Roussel","year":"2021","journal-title":"Blood Advances"},{"issue":"15","key":"10.1016\/j.trsl.2026.10.004_bib0056","doi-asserted-by":"crossref","first-page":"4663","DOI":"10.1158\/1078-0432.CCR-18-4142","article-title":"Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis","volume":"25","author":"Datar","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.trsl.2026.10.004_bib0057","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1349081","article-title":"Relatlimab: a novel drug targeting immune checkpoint LAG-3 in melanoma therapy","volume":"14","author":"Su","year":"2024","journal-title":"Frontiers in Pharmacology"},{"issue":"9","key":"10.1016\/j.trsl.2026.10.004_bib0058","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental Mechanisms of Immune Checkpoint Blockade Therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discovery"},{"issue":"11","key":"10.1016\/j.trsl.2026.10.004_bib0059","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005548","article-title":"Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumors","volume":"10","author":"Natoli","year":"2022","journal-title":"Journal for ImmunoTherapy of Cancer"},{"issue":"6","key":"10.1016\/j.trsl.2026.10.004_bib0060","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.survophthal.2021.01.001","article-title":"Ocular side effects of checkpoint inhibitors","volume":"66","author":"Alba-Linero","year":"2021","journal-title":"Survey of Ophthalmology"},{"issue":"6","key":"10.1016\/j.trsl.2026.10.004_bib0061","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1080\/09273948.2021.1890133","article-title":"Risk of Ophthalmic Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis","volume":"30","author":"Hou","year":"2022","journal-title":"Ocul Immunol Inflamm"},{"issue":"6","key":"10.1016\/j.trsl.2026.10.004_bib0062","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.13727","article-title":"Immune Checkpoint Inhibitors for Patients With Preexisting Autoimmune Neurologic Disorders","volume":"8","author":"Fletcher","year":"2025","journal-title":"JAMA Network Open"},{"issue":"4","key":"10.1016\/j.trsl.2026.10.004_bib0063","doi-asserted-by":"crossref","first-page":"98","DOI":"10.36401\/JIPO-22-14","article-title":"Highlights on Ocular Toxicity of Immune Checkpoint Inhibitors at a US Tertiary Cancer Center","volume":"5","author":"Mazharuddin","year":"2022","journal-title":"Journal of immunotherapy and precision oncology"},{"issue":"9","key":"10.1016\/j.trsl.2026.10.004_bib0064","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1136\/bjophthalmol-2020-316970","article-title":"Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo Clinic experience","volume":"105","author":"Fortes","year":"2021","journal-title":"Br J Ophthalmol"},{"issue":"9","key":"10.1016\/j.trsl.2026.10.004_bib0065","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1093\/annonc\/mdv182","article-title":"A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors","volume":"26","author":"Chen","year":"2015","journal-title":"Annals of Oncology"},{"issue":"1","key":"10.1016\/j.trsl.2026.10.004_bib0066","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1080\/09273948.2020.1773867","article-title":"Ocular Adverse Events Induced by Immune Checkpoint Inhibitors: A Comprehensive Pharmacovigilance Analysis","volume":"30","author":"Bomze","year":"2022","journal-title":"Ocular Immunology and Inflammation"},{"key":"10.1016\/j.trsl.2026.10.004_bib0067","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1038\/s41433-024-03212-z","article-title":"Impact of immune checkpoint inhibitors on vision and eye health","volume":"38","author":"Masalkhi","year":"2024","journal-title":"Eye (Lond)"},{"issue":"3","key":"10.1016\/j.trsl.2026.10.004_bib0068","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.joco.2019.05.002","article-title":"Ocular adverse events with immune checkpoint inhibitors","volume":"31","author":"Fang","year":"2019","journal-title":"Journal of Current Ophthalmology"},{"issue":"5","key":"10.1016\/j.trsl.2026.10.004_bib0069","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14051699","article-title":"Update in the Diagnosis and Management of Ocular Surface Squamous Neoplasia (OSSN)","volume":"14","author":"Tsatsos","year":"2025","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.trsl.2026.10.004_bib0070","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1097\/IOP.0000000000002776","article-title":"Primary Treatment of Eyelid Conjunctival Melanoma with Immunotherapy: A Case Report","volume":"41","author":"Weiss","year":"2024","journal-title":"Ophthalmic Plastic & Reconstructive Surgery"},{"issue":"11","key":"10.1016\/j.trsl.2026.10.004_bib0071","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.jiac.2017.04.007","article-title":"Uveitis induced by programmed cell death protein 1 inhibitor therapy with nivolumab in metastatic melanoma patient","volume":"23","author":"Kanno","year":"2017","journal-title":"Journal of Infection and Chemotherapy"},{"key":"10.1016\/j.trsl.2026.10.004_bib0072","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajoc.2024.102025","article-title":"Periocular granulomatous inflammatory lesions mimicking conjunctival melanoma recurrence in the setting of systemic nivolumab treatment","volume":"36","author":"Tan","year":"2024","journal-title":"American Journal of Ophthalmology Case Reports"},{"key":"10.1016\/j.trsl.2026.10.004_bib0073","doi-asserted-by":"crossref","DOI":"10.1177\/1758835921992989","article-title":"Ocular adverse events associated with immune checkpoint inhibitors: a novel multidisciplinary management algorithm","volume":"13","author":"Shahzad","year":"2021","journal-title":"Ther Adv Med Oncol"},{"issue":"4","key":"10.1016\/j.trsl.2026.10.004_bib0074","doi-asserted-by":"crossref","first-page":"646","DOI":"10.18240\/ijo.2022.04.19","article-title":"Immune checkpoint inhibitor-associated ophthalmic adverse events: current understanding of its mechanisms, diagnosis, and management","volume":"15","author":"Zhou","year":"2022","journal-title":"International Journal of Ophthalmology"},{"issue":"7","key":"10.1016\/j.trsl.2026.10.004_bib0075","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002890","article-title":"Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors","volume":"9","author":"Guidon","year":"2021","journal-title":"Journal for ImmunoTherapy of Cancer"},{"issue":"3","key":"10.1016\/j.trsl.2026.10.004_bib0076","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/1759-7714.13327","article-title":"Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy","volume":"11","author":"Liu","year":"2020","journal-title":"Thoracic Cancer"},{"issue":"3","key":"10.1016\/j.trsl.2026.10.004_bib0077","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1007\/s10384-025-01307-y","article-title":"Clinical features and prognosis of immune checkpoint inhibitor-associated ocular inflammation in Japanese patients: a case series","volume":"70","author":"Yamae","year":"2026","journal-title":"Jpn J Ophthalmol"},{"issue":"2","key":"10.1016\/j.trsl.2026.10.004_bib0078","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.oret.2025.11.001","article-title":"Immune Checkpoint Inhibitor-Associated Uveitis: Predictors and Survival Impact","volume":"10","author":"Chew","year":"2026","journal-title":"Ophthalmol Retina"},{"issue":"5","key":"10.1016\/j.trsl.2026.10.004_bib0079","doi-asserted-by":"crossref","first-page":"e713","DOI":"10.1016\/j.jcjo.2025.02.010","article-title":"Association between immune checkpoint inhibitors and uveitis in patients with lung cancer, renal cell carcinoma, or malignant melanoma","volume":"60","author":"Iwai","year":"2025","journal-title":"Can J Ophthalmol"},{"issue":"7","key":"10.1016\/j.trsl.2026.10.004_bib0080","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.ophtha.2024.03.017","article-title":"Incident Noninfectious Uveitis Risk after Immune Checkpoint Inhibitor Treatment","volume":"131","author":"Chang","year":"2024","journal-title":"Ophthalmology"},{"key":"10.1016\/j.trsl.2026.10.004_bib0081","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1302293","article-title":"Association between immune checkpoint inhibitor medication and uveitis: a population-based cohort study utilizing TriNetX database","volume":"14","author":"Kuo","year":"2024","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.trsl.2026.10.004_bib0082","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1080\/09273948.2022.2159447","article-title":"Characteristics of Ocular Inflammatory Side Effects Associated with Immune Checkpoint Inhibitors in a Northern California Population","volume":"32","author":"Qian","year":"2024","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.trsl.2026.10.004_bib0083","article-title":"Association between immune checkpoint inhibitors and the risk and prognosis of uveitis: a meta-analysis","volume":"17","author":"Li","year":"2026","journal-title":"Front Immunol"},{"key":"10.1016\/j.trsl.2026.10.004_bib0084","article-title":"Ocular adverse events associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FAERS database","volume":"17","author":"Liu","year":"2026","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.trsl.2026.10.004_bib0085","article-title":"What is the incidence and clinical significance of dry eye disease in patients treated with immune checkpoint inhibitors? A systematic review and meta-analysis of ocular immune-related adverse events","volume":"9","author":"Chen","year":"2026","journal-title":"Acta Ophthalmol. Published online March"},{"key":"10.1016\/j.trsl.2026.10.004_bib0086","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ejca.2020.11.027","article-title":"The association between immune checkpoint or BRAF\/MEK inhibitor therapy and uveitis in patients with advanced cutaneous melanoma","volume":"144","author":"Dimitriou","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.trsl.2026.10.004_bib0087","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12348-025-00484-8","article-title":"Immune checkpoint inhibitor-associated Vogt-Koyanagi-Harada-like syndrome: A descriptive systematic review","volume":"15","author":"Zhang","year":"2025","journal-title":"J Ophthalmic Inflamm Infect"},{"issue":"11","key":"10.1016\/j.trsl.2026.10.004_bib0088","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.ophtha.2020.05.003","article-title":"Immune Checkpoint Inhibitor-Associated Optic Neuritis","volume":"127","author":"Francis","year":"2020","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.trsl.2026.10.004_bib0089","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.ophtha.2020.09.027","article-title":"Immunotherapy for Conjunctival Squamous Cell Carcinoma with Orbital Extension","volume":"128","author":"Demirci","year":"2021","journal-title":"Ophthalmology"},{"issue":"36","key":"10.1016\/j.trsl.2026.10.004_bib0090","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.trsl.2026.10.004_bib0091","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"12","key":"10.1016\/j.trsl.2026.10.004_bib0092","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.trsl.2026.10.004_bib0093","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000550281","article-title":"Drug Rechallenge after Immune Checkpoint Inhibitor-Induced Inflammation and Optic Nerve Disorders","volume":"12","author":"Canestraro","year":"2026","journal-title":"Ocul Oncol Pathol"},{"key":"10.1016\/j.trsl.2026.10.004_bib0094","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ajo.2026.05.046","article-title":"Immune Checkpoint Inhibitor-Associated Uveitis: Insights From Comparative Analyses Across Malignancies and Drug Classes","volume":"289","author":"Bellanda","year":"2026","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.trsl.2026.10.004_bib0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2026.116594","article-title":"Optic neuropathies induced by immune checkpoint inhibitors: A case series and systematic review of the literature","volume":"237","author":"Cuzzubbo","year":"2026","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.trsl.2026.10.004_bib0096","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/WNO.0000000000002330","article-title":"Immune Checkpoint Inhibitor-Induced Ocular Myasthenia Gravis: Case Series and Literature Review","volume":"46","author":"Dezard","year":"2026","journal-title":"J Neuroophthalmol"},{"issue":"5","key":"10.1016\/j.trsl.2026.10.004_bib0097","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1080\/09273948.2026.2677094","article-title":"Immune Checkpoint Inhibitor-Associated Uveitis Treated with the 0.19 Mg Fluocinolone Acetonide Intravitreal Implant: Clinical Outcomes in a Retrospective Case-Series","volume":"34","author":"Lloren\u00e7","year":"2026","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.trsl.2026.10.004_bib0098","article-title":"Ocular Surface Disease as an Immune-related Adverse Event of Immune Checkpoint Inhibitor Therapy","volume":"9","author":"Frey","year":"2026","journal-title":"Cornea. Published online September"},{"key":"10.1016\/j.trsl.2026.10.004_bib0099","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2026.1845963","article-title":"Pharmacovigilance analysis of immune checkpoint inhibitor-associated optic nerve toxicity based on the FAERS database","volume":"17","author":"Bao","year":"2026","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.trsl.2026.10.004_bib0100","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1001\/jamaophthalmol.2025.3159","article-title":"Multicenter Interspecialty Consensus on Experimental Oncology Drug-Related Ocular Adverse Event Reporting","volume":"144","author":"Pasricha","year":"2026","journal-title":"JAMA Ophthalmol"},{"issue":"13","key":"10.1016\/j.trsl.2026.10.004_bib0101","doi-asserted-by":"crossref","first-page":"5944","DOI":"10.3390\/ijms27135944","article-title":"Ophthalmic Immune-Related Adverse Events in Cancer Immunotherapy: Tissue-Specific Mechanisms, Clinical Phenotypes, and Consensus-Based Management","volume":"27","author":"Zong","year":"2026","journal-title":"Int J Mol Sci"},{"issue":"14","key":"10.1016\/j.trsl.2026.10.004_bib0102","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1167\/iovs.66.14.53","article-title":"Can Immune Checkpoint Modulation Redefine Ocular Immunotherapy? Emerging Mechanisms, Challenges, and Translational Opportunities-A Comprehensive Review","volume":"66","author":"Chen","year":"2025","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S193152442600215X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S193152442600215X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:01:57Z","timestamp":1793188917000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S193152442600215X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":102,"alternative-id":["S193152442600215X"],"URL":"https:\/\/doi.org\/10.1016\/j.trsl.2026.10.004","relation":{},"ISSN":["1931-5244"],"issn-type":[{"value":"1931-5244","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ocular Immune Toxicity in Cancer Immunotherapy, From Immune Privilege Breakdown to Treatment Rechallenge: A Review","name":"articletitle","label":"Article Title"},{"value":"Translational Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trsl.2026.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}